Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Receivables (2016 - 2025)

Haemonetics has reported Change in Receivables over the past 17 years, most recently at -$11.1 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$11.1 million for Q4 2025, down 724.39% from a year ago — trailing twelve months through Dec 2025 was -$17.7 million (down 10245.61% YoY), and the annual figure for FY2025 was -$7.0 million, down 128.75%.
  • Change in Receivables for Q4 2025 was -$11.1 million at Haemonetics, down from $7.3 million in the prior quarter.
  • Over the last five years, Change in Receivables for HAE hit a ceiling of $30.6 million in Q4 2023 and a floor of -$25.5 million in Q2 2021.
  • Median Change in Receivables over the past 5 years was $911000.0 (2023), compared with a mean of $2.2 million.
  • Peak annual rise in Change in Receivables hit 618.57% in 2024, while the deepest fall reached 7060.78% in 2024.
  • Haemonetics' Change in Receivables stood at $9.2 million in 2021, then fell by 20.63% to $7.3 million in 2022, then soared by 317.63% to $30.6 million in 2023, then plummeted by 94.21% to $1.8 million in 2024, then crashed by 724.39% to -$11.1 million in 2025.
  • The last three reported values for Change in Receivables were -$11.1 million (Q4 2025), $7.3 million (Q3 2025), and -$3.6 million (Q2 2025) per Business Quant data.